Trial · NCT07146646
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
NCT07146646, Phase 2, Suspended, Case Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer. Trials, record NCT07146646. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07146646
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
- NCT number
- NCT07146646
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 27 participants, estimated
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma
- Interventions
- Trifluridine/tipiracil, Oxaliplatin
- First posted
- 2025-08-28
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease control rate (DCR) by RECIST v1.1 | Every 8 weeks until treatment discontinuation, up to 6 months | DCR is the percentage of participants whose cancer did not get worse after treatment (i.e. the percentage of participants who had CR, PR, or SD, as defined below), and this will be measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions. Partial Response (PR) is defined as a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD) is defined as a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of one or more new lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
| Secondary | Safety and tolerability | Day 1 | Measured by the grade of adverse events (AEs) per CTCAE version 5.0 |
| Secondary | Safety and tolerability | At treatment discontinuation, up to 6 months | Measured by the grade of adverse events (AEs) per CTCAE version 5.0 |
| Secondary | Safety and tolerability | 30 days post-study treatment discontinuation, up to 6 months | Measured by the grade of adverse events (AEs) per CTCAE version 5.0 |
| Secondary | Safety and tolerability | Day 1 | Measured by the incidence of adverse events (AEs) |
| Secondary | Safety and tolerability | At treatment discontinuation, up to 6 months | Measured by the incidence of adverse events (AEs) |
| Secondary | Safety and tolerability | 30 days post-study treatment discontinuation, up to 6 months | Measured by the incidence of adverse events (AEs) |
| Secondary | Safety and tolerability | Day 1 | Measured by the duration of adverse events (AEs) |
| Secondary | Safety and tolerability | At treatment discontinuation, up to 6 months | Measured by the duration of adverse events (AEs) |
| Secondary | Safety and tolerability | 30 days post-study treatment discontinuation, up to 6 months | Measured by the duration of adverse events (AEs) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07146646
GET https://conductscience.org/api/trials/v1/NCT07146646/registered